🇺🇸 PF-05280014 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 2 reports (18.18%)
  2. Ageusia — 1 report (9.09%)
  3. Alopecia — 1 report (9.09%)
  4. Anaemia — 1 report (9.09%)
  5. Aphasia — 1 report (9.09%)
  6. Asthenia — 1 report (9.09%)
  7. Confusional State — 1 report (9.09%)
  8. Decreased Appetite — 1 report (9.09%)
  9. Diarrhoea — 1 report (9.09%)
  10. Dizziness — 1 report (9.09%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is PF-05280014 approved in United States?

PF-05280014 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for PF-05280014 in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.